The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

计划入组 47 人 · 首次发布于 2021 年 9 月 29 日

AB154 Combined With AB122 for Recurrent Glioblastoma

计划入组 46 人 · 首次发布于 2020 年 12 月 7 日

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

计划入组 125 人 · 首次发布于 2021 年 2 月 1 日

Renvistobart

Anti TIGIT antibody(Biocytogen)

recombinant humanized anti-TIGIT antibody

Cambridge Antibody Technology

New Zealand

Latticon Antibody Therapeutics, Inc

United States

Novel Anti-Infective Technologies, LLC

iTeos Secures $120M Funding to Advance TIGIT Antibody Program in NSCLC

Novel Anti-TIGIT Therapy Shows Significant Survival Benefit in Advanced Liver Cancer Trial

MSD Discontinues Development of TIGIT and LAG-3 Cancer Immunotherapy Programs